Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline

Core Insights - Intellia Therapeutics reported a narrower loss of 83 cents per share for Q4 2025, compared to a loss of $1.27 per share in the same quarter last year, and better than the Zacks Consensus Estimate of a loss of 99 cents [1][7] - The company generated revenues of $23 million in Q4 2025, significantly exceeding the Zacks Consensus Estimate of $12 million, marking a 73.8% year-over-year increase driven by collaboration revenues [2][7] - Intellia's stock rose by 6.4% following the positive earnings report, with a 24% increase over the past six months, outperforming the industry average of 22.4% [3] Financial Performance - Research and development expenses for Q4 totaled $88.7 million, a decrease of 24.1% from the previous year, attributed to lower employee-related expenses and stock-based compensation [4] - General and administrative expenses increased by 2.2% year-over-year to $33.1 million [4] - For the full year 2025, Intellia reported revenues of $67.7 million, up from $57.9 million in 2024, with a loss of $3.81 per share, an improvement from a loss of $5.25 per share in the prior year [9] Cash Position - As of December 31, 2025, Intellia had cash, cash equivalents, and marketable securities totaling $605.1 million, down from $669.9 million as of September 30, 2025 [5] Pipeline Developments - Intellia is developing lonvo-z for hereditary angioedema (HAE), with top-line data expected by mid-2026 and a potential U.S. launch in the first half of 2027 [7][13] - The FDA lifted the clinical hold on the IND for the phase III study of nexiguran ziclumeran (nex-z), with enrollment expected to complete in the second half of 2026 [11][12] - Intellia is currently working with the FDA to resolve the clinical hold on the MAGNITUDE study for nex-z [12]